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The hormonal composition of follicular fluid and
its implications for ovarian cancer pathogenesis
Megan M Emori and Ronny Drapkin
*
Abstract
Ovulation has long been associated with an increased risk in ovarian cancer, yet the underlying molecular
mechanisms remain obscure. Two aspects of ovulation have been linked to ovarian cancer pathogenesis. The first is
the impact of repetitive tissue injury and repair that occurs with each ovulatory event. The second is the release of
follicular fluid that accompanies the follicular rupture and its effect on the ovarian and fallopian tube epithelial cells.
Hormones are an important component of follicular fluid, which transiently bathes the ovarian surface and fallopian
tube epithelium during ovulation. Much work has been done exploring the role of hormones in fertility, but some,
such as estrogen, have also been implicated in the pathogenesis of ovarian and other cancers. Understanding the
role of hormones within follicular fluid, as well as how they are altered in disorders which increase ovarian cancer
risk, will enhance our ability to assess risk and develop preventative strategies. This review provides an in depth
discussion of the logistics of using and studying follicular fluid in ovarian cancer research, and discusses the
fluctuations in follicular fluid hormone levels during normal physiological processes versus conditions that increase
ovarian cancer risk.
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Background
Despite our growing understanding of the cancer gen-
ome and the evolution of targeted therapies, ovarian
cancer remains the most lethal gynecological malignancy
in the Western world [1]. The clinical outcomes for this
disease have not changed significantly over the past four
decades, in large part due the lack of early detection
tools and the almost inevitable emergence of chemo-
resistant disease [1]. Adding to the complexity of this
cancer is its heterogenous nature. Although ovarian tu-
mors can arise from three different cell types: epithelial
cells, germ cells, and sex cord stromal cells, the vast
majority of ovarian cancers are epithelial in nature. Even
within epithelial ovarian cancers there exist various
histologic subtypes and molecular subgroups. This has
prompted the classification of epithelial ovarian cancers
into two groups. Type I tumors, clearly linked to ovarian
precursor lesions, encompass all histologic subtypes in-
cluding low grade serous, endometriod, mucinous, and
clear cell carcinomas. They are defined by their slow
growth and multiple genetic mutations. In contrast, Type
II tumors are highly aggressive, confer a much poorer
prognosis, and many have been linked to precursors aris-
ing from the fallopian tube epithelium. High Grade Serous
Ovarian Cancer (HGSOC) is the most common of the
Type II tumors. Type I and Type II tumors are also geno-
mically distinct. Type I tumors are frequently associated
with specific mutations in oncogenes such as k-RAS and
ARID1A [2]. In Type II tumors, TP53 is mutated in the
vast majority of tumors (96-100%) and appears to be the
earliest genetic event in HGSOC. BRCA1 and BRCA2
mutation carriers are particularly susceptible to Type II
tumors [2,3].
While much work has been done to characterize the
pathology and genetics of ovarian cancer, we still lack a
basic understanding of the early events and causes of this
disease. Our current understanding of the risks factors
of HGSOC derives primarily from epidemiological data.
Lifetime ovulation is positively correlated with HGSOC,
and factors such as parity and birth control, which de-
crease lifetime ovulation, have a protective effect against
HGSOC [4,5]. Establishing a molecular mechanism link-
ing ovulation and HGSOC pathogenesis is critical to
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Models of ovarian cancer pathogenesis
The origins of ovarian cancer are complex and still under
debate. New theories suggest that different ovarian tumor
subtypes have different origins, with the ovarian surface
epithelium implicated in Type 1 tumors and fallopian tube
secretory epithelial cells implicated in high grade serous
ovarian cancer [2,3,6]. The adherent mesothelium of the
ovary attracts both shed fallopian tube cells as well as
endometriosis-derived Müllerian tissue, further blurring
the lines of the ovary vs. Müllerian tissue debate [7].
Understanding the various cells of origin in ovarian
cancer similarly informs our understanding of ovarian
cancer pathogenesis. Several models have been posited
to explain how epidemiological factors such as menstru-
ation and ovulation may lead to ovarian cancer. A long
standing hypothesis, often called the Incessant Ovulation
Hypothesis, suggests that the repetitive wounding and
healing of the ovarian surface epithelium and adjacent
tubal epithelium that is induced by monthly ovulation in-
creases cell proliferation and thus the likelihood of gen-
omic instability which could lead to oncogenesis (Figure 1)
[4]. Another hypothesis, known as the Gonadotropin hy-
pothesis, implicates excessive direct and indirect stimula-
tion of the ovarian surface epithelium by gonadotropins,
leading to differentiation, proliferation, and ultimately ma-
lignant transformation (Figure 1) [5]. More recently, the
Incessant Menstruation hypothesis suggests that repeated
exposure to retrograde menstruation exposes the ovary
and fallopian tube to reactive oxygen species and oxidative
iron from the blood [8]. Lastly, several recent papers have
focused on damage induced by inflammation-mediated
factors found in the follicular fluid [9,10]. The recur-
ring theme in all these hypotheses is the incessant ovula-
tory damage. This reinforces the importance of ovulation,
but also makes it difficult to separate the impact of
each hypothesis as they are physiologically intercon-
nected. Women with altered steroid hormone levels, such
as those with Polycystic Ovarian Syndrome (PCOS), tend
to ovulate sporadically, while women who take oral con-
traceptives receive the protective benefits of both lowered
gonadotropin levels and inhibited ovulation [5,11]. The
average age of onset in ovarian cancer is postmenopausal,
at age 63, when hormonal levels have shifted and ovula-
tion has stopped [12]. Thus, an unanswered question that
also remains is why menopause is so temporally important
to the onset of the disease.
Ovulation and follicular fluid
Mature human follicles reach approximately 23 mm in
diameter, yielding upwards of 5 mL of follicular fluid
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Physical rupture of ovulation causes damage.
DNA damage incurred by exposure to FF ROS,
growth factors, and hormones.
Figure 1 Proposed mechanisms of HGSOC pathogenesis. Incessant Ovulation Hypothesis: monthly physical damage from ovulation
necessitates increased cell proliferation during repair, eventually leading to genomic instability. Gonadotropin hypothesis: Exposure to
hormones released during ovulation inhibits natural apoptosis, uninterrupted hormonal fluctuations stimulate differentiation, proliferation,
and ultimately malignant transformation.
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thelium and fallopian tube (FT) fimbria proximal to the
ovary. The debate over whether the ovarian surface epi-
thelium (OSE) or the FT fimbria is the cell of origin for
HGSOC is discussed in detail elsewhere [6,14]. For the
purposes of this review, both tissues are exposed to the
risk factors associated with ovulation. While there is ro-
bust epidemiologic data correlating total ovulatory events
to ovarian cancer risk, a biological explanation remains
elusive. One possibility recently proposed is that FF is gen-
otoxic to exposed epithelia (OSE and FTE) and that re-
petitive exposure to this fluid can lead to mutations and
alterations that drive neoplastic transformation [15]. The
composition of this fluid, known to play a critical role in
the development of the follicle, has profound reproductive
and pathogenic implications.
FF is initially derived from, and is similar in compos-
ition to, thecal capillary serum [16-18]. As the follicle de-
velops, granulosa cells produce large polysaccharides,
hormones, and growth factors which cannot pass the 100
kDA follicle-blood barrier, causing an osmotic gradient
which further increases FF volume [19,20]. Ultimately,
mature follicles in unstimulated women can contain as
much as 1,000 fold higher levels of estrogen and proges-
terone than the serum, whereas other hormones such as
follicle stimulating hormone (FSH) are not differentially
concentrated [21]. Other potentially harmful factors, such
as reactive oxygen species (ROS), have a physiologic win-
dow; their presence is required for embryo formation
but particularly high levels within the FF are associ-
ated with poor embryo formation in IVF patients [22].
While FF components include hormones, fatty acids, in-
flammatory factors, reactive oxygen species, and growth
factors, it is unclear what role these potentially anti-
apoptotic and mutagenic components play in ovarian can-
cer pathogenesis [9,10,23].
Follicular fluid sources
Follicular fluid is often studied in the context of live-
stock reproduction, and abattoirs provide a readily avail-
able source of whole ovaries and fallopian tubes. While
valuable research has been obtained using non-human
models, the advantages of increased follicle volume and
sample availability must be considered against the limited
relevance of working with non-human FF [24]. Humans are
the only known mammals to develop ovarian cancer natur-
ally, and the levels of major hormones in cow and camel
follicles is known to be several orders of magnitude lower
than their human counterparts [25,26]. Domesticated laying
hens, despite being oviparous, provide a unique model in
that they are extremely susceptible to ovarian cancer and
reflect several aspects of human disease [27]. Thus, a close
examination of human FF, though harder to obtain and
manipulate, is most relevant to studying the relationship
between FF composition and ovarian cancer pathogenesis
in humans.
Many recent studies have been conducted on the com-
position of human FF to assess conditions which are linked
to ovarian cancer risk, as well as the efficacy and prognos-
tic value of various in vitro fertilization (IVF) methods.
This review gathers the most recent studies where human
FF factors have been measured and comprehensively ex-
amines their fluctuation both under normal conditions and
due to various conditions or treatments which are linked
to HGSOC risk, and any role they may play in cancer
pathogenesis (Table 1). Ultimately, developing a better un-
derstanding of FF and its hormonal composition will illu-
minate its potential role in ovarian cancer pathogenesis.
The role of hormones in follicle development,
fertility, and cancer pathogenesis
Estradiol
Function
One of the most prominent components of FF, estradiol
(E2), is dominant between the mid-follicular and pre-
ovulatory phases (Figure 1). Mouse models lacking E2 fail
to develop mature follicles [28,29]. With regards to cancer,
estradiol is also thought to have a mutagenic effect, par-
ticularly in female reproductive tissue where elevated
blood levels of estrogens have been associated with an in-
creased risk of breast and uterine cancer [30,31]. Since
follicular fluid E2 concentrations can reach 1000 fold that
of serum levels, estradiol may also play a role in HGSOC
pathogenesis [21]. The two main oncogenic mecha-
nisms proposed for estrogen are indirect stimulation of
cell growth, leading to an increased risk of transcriptional
errors, and direct generation of DNA damage, particularly
through the production of free-radicals [32]. A detailed re-
view of estrogen’s direct and indirect mutagenic effects
can be found elsewhere [31].
Pathological and physiological conditions
Studying E2 levels in women with reproductive abnor-
malities gives insight into infertility as well as long term
cancer risk. Surprisingly, women with PCOS, known to
have elevated serum E2 levels, showed no difference in
their FF E2 when compared to male factor infertility
controls [33]. Similarly, no difference in FF E2 was ob-
served in women with endometriosis and male factor in-
fertility controls [34].
The role of infertility in HGSOC risk versus the role of
confounding infertility treatments is currently poorly under-
stood. Studies measuring hormone levels in women who re-
quired large amounts of stimulation to ovulate and control
subjects undergoing unstimulated In Vitro Fertilization
(IVF) found that while older age decreased FF E2 levels,
young low responders were comparable to control donors
[21]. Further studies measuring FF E2 levels in women
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firmed that FF E2 levels decrease with age, but are higher
in younger women with low ovarian reserve compared to
control donors [35]. This is consistent with blood serum
levels of estradiol, which decrease over a woman’sr e p r o -
ductive life cycle and are lowest at menopause [36]. In
general, it appears that in IVF stimulation suppresses the
level of FF E2 as measured in young, healthy egg donors
[37]. Unlike its clear role in uterine physiology and path-
ology, estrogen’s contribution to ovarian cancer remains




The most abundant hormonal component of FF, proges-
terone (P4) is critical for the end stages of follicle devel-
opment and for ovulation [29]. Knockout mice lacking
progesterone fail to ovulate [38]. The role of progester-
one is difficult to discern as increased levels of estrogen
induce the production of progesterone receptors, inex-
tricably linking their functions and responses [39]. Com-
pared to E2, cellular responses to progesterone are much
more diverse and therefore harder to implicate [40]. The
molecular role of progesterone in HGSOC pathogenesis
is unclear, but cumulative intake of specific exogenous
progestins has no impact on risk except when combined
with estrogen in oral contraceptives [41].
Pathological and physiological conditions
In the general population, it appears that age rather than
infertility impacts FF P4 levels, and that P4 levels rise as
a woman ages. In a study comparing low responders to
control donors, P4 levels were the same between youn-
ger donors and young low responders, but higher in
older low responders [21]. Similarly, young women with
an o r m a lo v a r i a nr e s e r v eh a dl o w e rF FP 4l e v e l st h a nt h e i r
low ovarian reserve counterparts or older women [35].
Where follicular estrogen remained constant in both endo-
metriosis and PCOS patients, follicular progesterone levels
were markedly decreased in both groups [33,34].
In young, healthy egg donor populations, it appears
that stimulating egg production has no effect on the FF
P4 when compared to unstimulated donors [37]. How-
ever, in patients undergoing IVF, the current evidence is
conflicting. The role of progesterone, while generally
considered protective in breast cancer, remains unclear
in the context of ovarian cancer.
Androgens
Function
Androgens, although predominantly involved in male de-
velopment, are also expressed in the ovary and fallopian
tube and play a critical role in early follicle development
[42,43]. The role of androgens on follicle development is
species dependent, and humans are the only mammal not
known to exhibit a decrease in AR as the follicle matures
[28,33,44]. Female mice lacking a functional androgen re-
ceptor (AR) are less fertile and have a shorter reproductive
window [42,43].
Pathological and physiological conditions
Unlike estrogen and progesterone, testosterone levels in
mature follicles seem resistant to fluctuation, as women
with infertility or IVF treatments are remarkably similar to
their control counterparts. Follicular testosterone levels,
uniquely to humans, continue rise as the follicle develops
[33,44]. In patients with unstimulated cycles, testosterone
was not significantly affected by age or responder status,
with all patients comparable to donor controls [21]. As
Table 1 FF factors and their role in follicle development and cancer pathogenesis
Factor Role in follicle development Potential role in pathogenesis Mouse knockout model effect
Estradiol Follicle development (specifically
mid-follicular to pre-ovulatory
phases) [28,29]
Direct proliferatory effect [32], free radical generation [32],
epidemiological risk factor for breast and uterine cancers [30]
Failure to develop mature
follicles [28]
Progesterone End stage follicle development
[28,29]
Progestin containing oral contraceptives decrease ovarian
cancer risk [41]
Failure to ovulate [28]
Androgens Stimulates early follicle
development [28]
Unknown Decrease in fertility,
granulosa cell number [28]
FSH Stimulation of primordial
follicles, dominant follicle
selection [45]
Hormonal regulator of estrogen, progestrone, testosterone,
FSH and its signaling pathways highly expressed in OVCAR
cell lines [46,51]
Failure to ovulate, failure of
primordial follicles to mature [46]
AMH Inhibits primordial follicle
growth [56].
Promotes growth and differentiation [54], elevated in granulosa cell
tumors [62]. Unlikely player in HGSOC as matched controls have no
difference in serum AMH, no correlation to stage or prognosis [63]
Fertile but with shorter period
of fertility [56]
LH Supports thecal steroidogenesis,
induces ovulation and corpus
luteum formation [64]
Promotes angiogenesis in EOC through PI3K/AKT-mTOR pathway,
inhibits apoptosis and cisplatin mediated apoptosis in EOC [69,70]
Atrophied ovaries, hypogonadism,
malformed antral follicles, no
corpus lutea [66]
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were compared to women with male factor infertility, fol-
licular testosterone levels were significantly higher in
women with PCOS [33]. Stimulation in egg donors only
slightly elevates the levels of FF testosterone as compared
to their unstimulated donor controls [37].
Follicle stimulating hormone
Function
FSH stimulates the development of primordial follicles
and, through a feedback loop, maintains and selects the
dominant follicle [45]. Mutant mice lacking the FSH-
receptor are anovulatory. This is likely due to the fact
that FSH blocks apoptosis in preantral follicles [46,47].
FSH-R knockout mouse models also lack circulating es-
trogen and have significantly less progesterone, while
serum testosterone levels are increased, suggesting that
FSH is also involved in hormonal regulation [46].
FSH serum levels rise at puberty and peak at meno-
pause [45-47]. In younger women, high levels of serum
FSH are indicative of ovary feedback dysfunction and are
symptomatic of low ovarian reserve [47,48]. A notable
exception to this is PCOS, where serum FSH levels are
abnormally low [49].
Pathological and physiological conditions
Although follicular FSH is infrequently measured, it ap-
pears to be generally resistant to change. While one study
confirmed that both women approaching menopause and
young women who responded poorly to stimulation had
high levels of follicular FSH, another found that neither
ovarian reserve nor age altered FF FSH levels [21,35]. Al-
though levels of follicular FSH have yet to be measured in
PCOS patients, they do not appear to be affected by endo-
metriosis [34]. Surprisingly, it is one of the few follicular
hormones unaltered by IVF stimulation [37].
New research has emerged showing FSH to be highly
elevated in a number of solid tumors. FSH is thought to
be beneficial for oncogenesis in that it increases angiogen-
esis via the Vascular Endothelial Growth Factor (VEGF)
pathway [50]. Given the rise of serum FSH in menopausal
women that corresponds to the typical onset of ovarian
cancer, it is worth noting that FSH has been shown to in-
hibit apoptosis in a variety of ovarian cancer subtypes
in vitro [51]. One of the signaling pathways regulated by
FSH, OCT4, is also highly expressed in a variety of ovarian
cancer cell lines and tumor samples, and has been shown
to be involved in inhibiting apoptosis and inducing
chemo-resistance, as well as stem cell regulation [52,53].
Less is known about the role of FSH within the follicle,
but taken together these findings suggest that FSH may be
a hormone of particular interest in the induction and
growth of ovarian tumors.
Anti-müllerian hormone
Function
Anti-Müllerian hormone (AMH), is a transforming growth
factor produced by the granulosa cells and involved in both
growth and differentiation [54,55]. In the ovary, it func-
tions to inhibit primordial follicle growth. AMH null mice
are fertile and have fully developed ovaries but a much
smaller fertility window [56]. AMH serum levels increase
significantly in early childhood, peak in the early 20s, then
decline until becoming undetectable at menopause [55,57].
During the menstrual cycle, AMH decreases sensitivity to
FSH, and is negatively correlated with both FSH and estra-
diol [58-61] It is generally agreed upon that AMH is a
marker of follicle status and is not affected by fluctuations
in other hormones [59].
Pathological and physiological conditions
Follicular levels of AMH closely mimic those of the serum,
decreasing with age and decreased ovarian reserve, and
negatively correlated with follicular FSH [35,61]. AMH
has recently been identified as uniquely elevated in granu-
losa cell tumors, and is currently being evaluated as a
marker to track the recurrence of this disease [62]. How-
ever, for the more common epithelial ovarian cancers,
serum AMH does not appear to differ from that of age-
matched controls, nor does it correlate with stage of
tumor or prognosis [63].
Luteinizing hormone
Function
Luteinizing hormone (LH) is produced by the anterior
pituitary gland [64] and is responsible for supporting ste-
roidogenesis within LH receptor positive thecal cells
[65]. Mice who are deficient in LH are infertile, exhibit
atrophied ovaries, and have low serum levels of estradiol
and progesterone [66]. Surprisingly, serum FSH levels
remain unaffected in these models [66]. Over the course
of a woman’s lifetime, serum LH levels will rise, peaking
at menopause [36,67,68].
Pathological and physiological conditions
While LH serum levels are known to rise at menopause
[36,68], follicular fluid levels of LH remain surprisingly
stable throughout the reproductive window. No differ-
ence was found in the LH follicular fluid levels between
young and aging women in multiple studies [21,35]. Fertil-
ity status also appeared irrelevant to follicular LH levels, as
low responders and women with reduced ovarian reserves
of all ages had similar levels, even compared to their young,
un-induced counterparts [21,35]. Another study comparing
endometriosis patients to male infertility controls found
no difference in follicular LH levels as well [34]. While
comorbidities and aging do not seem to affect follicu-
lar LH levels, stimulation with rFSH and recombinant
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within the follicle by approximately 100 fold [37].
Recently, LH has been implicated in epithelial ovarian
cancer (EOC) as an enhancer of angiogenesis. Working
through the PI3K/AKT-mTOR pathway, LH is capable of
inducing VEGF, thereby implicating its involvement in cell
growth, invasion, and migration [69]. LH has also been
shown to upregulate survivin, inhibiting apoptosis in epi-
thelial ovarian cancer [70]. Of particular interest is the fact
that EOC cells treated with LH are much less sensitive to
cisplatin induced apoptosis, suggesting a mechanism of
drug resistance [70].
Technical considerations
While the microenvironment is critical to early ovarian
cancer pathogenesis, several technical problems have pla-
gued efforts to study it in detail. Access to follicular fluid
features prominently on this list, as do lack of proper con-
trols. For women who have been induced in the course of
infertility treatments, multiple mature follicles and manual
egg retrieval mean follicular fluid supply is plentiful, but at
the expense of altered hormone levels. Oophorectomies,
which often accompany hysterectomies, would provide a
valuable source of unadulterated follicles except that these
are generally performed later in life when the ovaries have
atrophied. Very few experiments, with a few valuable ex-
ceptions, recruit young female volunteers for egg retrieval,
severely limiting our knowledge of baseline hormonal
composition [20,36]. Thus one of the main goals in this
field should be to determine the separate risk factors of
nulliparity and conditions which lead to infertility.
Conclusions
The hormonal profile of follicular fluid is complex and
constantly in flux, changing dramatically over the course
of follicle development, as well as throughout a woman’s
lifetime depending on her age, health status and fertility.
Understanding the hormonal microenvironment of ovu-
lation is critical to establishing a molecular link between
incessant ovulation and early ovarian cancer pathogen-
esis. While studying the role of hormones in ovulation is
important, no less important is the role of hormones in
the transition to menopause, when ovarian cancer is typic-
ally diagnosed. Why this disease so often manifests itself
after risk factors such as ovulation have come to an end,
and when supposedly protective progesterone levels have
risen and likely damaging estrogen levels are low is a puz-
zle at the crux of the ovarian cancer problem [21,35]. In
the efforts to understand disease onset, cessation of ovula-
tion and the hormonal milieu accompanying it will be as
important as ovulation itself.
Currently, one of the most promising leads providing
a molecular basis for the contribution of FF to ovarian
cancer pathogenisis was reported by Bahar-Shany et al.
[15]. Using human fallopian tube ex-vivo cultures and
pooled human FF, they found that exposing fallopian tube
epithelium to FF stimulated inflammatory and DNA
repair pathways and resulted in the upregulation of pro-
angiogenic and pro-inflammatory interleukin 8. They no-
ticed that follicular fluid exposure led to DNA double
stranded breaks and, consequently, the stabilization of the
tumor suppressor TP53. Early precursors of high grade
serous ovarian cancer are also defined by their high ex-
pression of TP53 and high levels of DNA damage, al-
though in the vast majority of these cases TP53 is also
mutated, often with a gain of function mutation [71]. Un-
derstanding the link between the temporary induction of
TP53 in response to FF exposure and the aquisition of
mutations in P53 in early precursor lesions will be key in
the future of ovarian cancer research.
The role of hormones in the later stages of ovarian
cancer is also a field ripe for study. The relationship be-
tween hormonal microenvironment and tumor is compli-
cated, in no small part because the hormone receptors of
many primary tumors and ovarian cancer cell lines have
been inactivated either directly or indirectly. The lack of
response to hormone signaling is evidenced by the largely
unsuccessful use of hormonal therapy in ovarian cancer,
especially compared to its sweeping successes in breast
cancer [72,73].
In the fight against ovarian cancer, many factors beyond
the hormonal milieu play a role, and follicular fluid is by
no means the sole initiator of tumorigenesis. Other theor-
ies, including telomere shortening [74,75] have been pro-
posed as well. Ultimately, providing the molecular link
between epidemiologic risk factors and disease mecha-
nisms will have broad implications not only for ovarian
cancer, but for infertility and development as well.
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